You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,858,996


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,858,996
Title:Pharmaceutical compositions for the coordinated delivery of NSAIDS
Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen Inc. (Chapel Hill, NC)
Application Number:14/244,471
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,858,996
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;
Patent landscape, scope, and claims:

United States Patent 8,858,996: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 8,858,996, assigned to Horizon Medicines LLC, is a significant patent in the pharmaceutical industry, particularly in the treatment of various arthritic conditions. This patent covers a method for achieving pain and symptom relief with a reduced risk of gastrointestinal damage. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Background of the Patent

The patent in question, U.S. Patent 8,858,996, pertains to Vimovo®, a drug formulation that combines naproxen and esomeprazole magnesium. This formulation is designed to treat symptoms of osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis, while minimizing the risk of gastrointestinal damage such as ulcers, erosions, and hemorrhages[2].

Scope of the Patent

The scope of U.S. Patent 8,858,996 is defined by its claims, which outline the specific method and composition of the drug formulation. The patent covers a combination of a nonsteroidal anti-inflammatory drug (NSAID), specifically naproxen, and a proton pump inhibitor (PPI), specifically esomeprazole magnesium. This combination is intended to provide therapeutic benefits while reducing the gastrointestinal side effects associated with NSAID use[2].

Claims of the Patent

The patent includes multiple claims that define the invention. These claims are critical in determining the patent's scope and validity. For instance, claims 1-19 of the '996 patent specify the method of treatment, the composition of the drug, and the dosage forms. These claims are detailed and specific, aiming to protect the unique combination and method of administration of the drug[5].

Patent Landscape

Related Patents and Applications

The '996 patent is part of a larger patent family that includes other related patents, such as U.S. Patent 9,161,920. These patents collectively cover various aspects of the drug formulation and its method of use. Understanding the entire patent family is crucial for assessing the overall patent landscape and potential challenges to the patents' validity[2].

International Patent Landscape

To fully understand the global implications of U.S. Patent 8,858,996, it is essential to search international patent databases. Resources such as the European Patent Office's esp@cenet, the Japan Patent Office, and the World Intellectual Property Organization's PATENTSCOPE can provide insights into whether similar patents or applications exist in other jurisdictions[1].

Challenges to the Patent

Validity and Enforceability

The validity and enforceability of U.S. Patent 8,858,996 have been challenged in court. In the case of Horizon Meds. LLC v. Dr. Reddy’s Labs., Inc., Dr. Reddy’s Labs challenged the patent's validity, arguing that the asserted claims lacked adequate written description. The court denied the plaintiffs' motion for a preliminary injunction, citing substantial questions about the patent's validity based on the written-description requirement[2].

Written Description Requirement

The written description requirement is a critical aspect of patent law, ensuring that the patent specification adequately describes the claimed invention. In this case, Dr. Reddy’s Labs argued that the specification did not provide sufficient support for the claimed method, particularly regarding the effective uncoated esomeprazole. This challenge highlights the importance of thorough and detailed patent specifications to withstand validity challenges[2].

Search and Analysis Tools

USPTO Resources

The United States Patent and Trademark Office (USPTO) provides several tools for searching and analyzing patents. The Patent Public Search tool, for example, offers enhanced access to prior art and can be used to search for related patents and applications. Additionally, resources like the Global Dossier and the Common Citation Document (CCD) can help in understanding the global patent family and citation data related to the patent[1].

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset is another valuable resource for analyzing patent claims. This dataset contains detailed information on claims from U.S. patents and applications, which can be used to understand the scope and trends in patent claims, including those related to U.S. Patent 8,858,996[3].

Conclusion

U.S. Patent 8,858,996 is a significant patent in the pharmaceutical industry, covering a unique drug formulation designed to treat arthritic conditions while minimizing gastrointestinal risks. Understanding the scope, claims, and challenges to this patent is crucial for both the patent holders and potential challengers. The patent landscape is complex, with international implications and ongoing legal challenges that highlight the importance of robust patent specifications and thorough search and analysis.

Key Takeaways

  • Scope and Claims: The patent covers a specific method and composition of a drug formulation combining naproxen and esomeprazole magnesium.
  • Challenges: The patent has faced challenges regarding its validity, particularly the written-description requirement.
  • International Landscape: Searching international patent databases is essential for understanding global implications.
  • USPTO Resources: Tools like the Patent Public Search and Global Dossier are vital for thorough patent analysis.
  • Legal Implications: Court cases like Horizon Meds. LLC v. Dr. Reddy’s Labs., Inc. highlight the importance of robust patent specifications.

FAQs

What is the main subject of U.S. Patent 8,858,996?

U.S. Patent 8,858,996 pertains to a drug formulation combining naproxen and esomeprazole magnesium, designed to treat arthritic conditions while reducing gastrointestinal risks.

What are the key claims of the patent?

The patent includes claims that specify the method of treatment, the composition of the drug, and the dosage forms, particularly focusing on the combination of naproxen and esomeprazole magnesium.

Why was the patent challenged in court?

The patent was challenged by Dr. Reddy’s Labs on the grounds that the asserted claims lacked adequate written description, specifically regarding the effective uncoated esomeprazole.

What tools can be used to analyze the patent?

Tools such as the USPTO's Patent Public Search, Global Dossier, and the Patent Claims Research Dataset are useful for analyzing the patent and its claims.

How does the international patent landscape affect this patent?

Searching international patent databases like those provided by the European Patent Office, Japan Patent Office, and World Intellectual Property Organization can reveal whether similar patents or applications exist globally, impacting the patent's validity and enforceability.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,858,996

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,858,996

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1411900 ⤷  Subscribe C300481 Netherlands ⤷  Subscribe
European Patent Office 1411900 ⤷  Subscribe 91858 Luxembourg ⤷  Subscribe
European Patent Office 1411900 ⤷  Subscribe 1190013-1 Sweden ⤷  Subscribe
European Patent Office 1411900 ⤷  Subscribe CA 2012 00036 Denmark ⤷  Subscribe
European Patent Office 1411900 ⤷  Subscribe 2011/016 Ireland ⤷  Subscribe
European Patent Office 1411900 ⤷  Subscribe SPC/GB11/015 United Kingdom ⤷  Subscribe
European Patent Office 1411900 ⤷  Subscribe C01411900/01 Switzerland ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.